{"doc_id": "si-2021-0121-reg-1", "parent_doc_id": "si-2021-0121", "section_id": "reg-1", "section_label": "Regulation 1.", "si_number": "S.I. No. 121 of 2021", "title": "(Amendment) Act 2016 (No. 9 of 2016)), 18 and 38 of the Misuse of Drugs Act", "year": 2021, "heading": "1. These Regulations may be cited as the Misuse of Drugs (Amendment)", "text_raw": "1. These Regulations may be cited as the Misuse of Drugs (Amendment) \n\nRegulations 2021.", "text_norm": "1 regulation may cited misuse drug (amendment) regulation 2021", "start_char": 590, "end_char": 681, "source_path": "downloads\\2021\\2021_0121.pdf", "extraction_method": "pdfminer", "checksum": "sha256:ecdc49e5b74d5c6708ad4abbd34865aa1da0e76781d29133906ffbccd93668e5", "cross_refs": []}
{"doc_id": "si-2021-0121-reg-2", "parent_doc_id": "si-2021-0121", "section_id": "reg-2", "section_label": "Regulation 2.", "si_number": "S.I. No. 121 of 2021", "title": "(Amendment) Act 2016 (No. 9 of 2016)), 18 and 38 of the Misuse of Drugs Act", "year": 2021, "heading": "2. The Misuse of Drugs Regulations 2017 (S.I. No. 173 of 2017) are", "text_raw": "2. The Misuse of Drugs Regulations 2017 (S.I. No. 173 of 2017) are \n\namended by the substitution of the following Schedule for Schedule 1: \n\nNotice of the making of this Statutory Instrument was published in \n“Iris Oifigiúil” of 23rd March, 2021. \n\n \n \n \n \n \n \n \n \n\f[121] 3 \n\n“Schedule 1", "text_norm": "2 misuse drug regulation 2017 (s.i no 173 2017) amended substitution following schedule schedule 1 notice making statutory instrument published iris oifigiuil 23rd march 2021 121 3 schedule 1", "start_char": 681, "end_char": 971, "source_path": "downloads\\2021\\2021_0121.pdf", "extraction_method": "pdfminer", "checksum": "sha256:ecdc49e5b74d5c6708ad4abbd34865aa1da0e76781d29133906ffbccd93668e5", "cross_refs": []}
{"doc_id": "si-2021-0121-reg-1", "parent_doc_id": "si-2021-0121", "section_id": "reg-1", "section_label": "Regulation 1.", "si_number": "S.I. No. 121 of 2021", "title": "(Amendment) Act 2016 (No. 9 of 2016)), 18 and 38 of the Misuse of Drugs Act", "year": 2021, "heading": "1. The following substance and products, namely-", "text_raw": "1. The following substance and products, namely- \n\n(a) N-(Adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide \n\n(otherwise known as Clockwork Orange, 5F AKB48) \n\nN-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2yl]-1-(cyclohexylmethyl)-1Hindazole-3-carboxamide (otherwise known as ADB-CHMINACA) \n\nN-(1-Amino-3,3-dimethyl-1-oxobutan-2yl)-1-(4-fluorobenzyl)-1H-indazole3-carboxamide (otherwise known as ADB-FUBINACA) \n\nN-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-(cyclohexylmethyl)-1Hindazole-3-carboxamide (otherwise known as AB-CHMINACA) \n\nN-[(2S)-1-Amino-3-methyl-1-oxobutan-2yl]-1-pentyl-1H-indazole-3carboxamide (otherwise known as AB-PINACA) \n\n5-(2-Aminopropyl)indole (otherwise known as 5-IT) \n\n1-(1,3-Benzodioxol-5-yl)-2-(1-pyrrolidinyl)-1-pentanone \n\nN-(1-Benzyl-4-piperidyl)propionanilide \n\n2-(4-Bromo-2,5-dimethoxyphenyl)-N-[(2methoxyphenyl)methyl]ethanamine (otherwise known as 25B-NBOMe) \n\n1-(4-Bromofuro[2,3-f][1]benzofuran-8-yl)propan-2-amine (otherwise known \nas BromodragonFLY) \n\nBufotenine \n\nCannabinol, except where contained in Cannabis or cannabis resin \n\nCannabinol derivatives, not being dronabinol or its stereoisomers \n\nCannabis (not being a preparation specified in paragraph 5 of Part 1 of \nSchedule 4 of the Misuse of Drugs Regulations 2017 (S.I. No. 173 of 2017) \nor a preparation or product specified in Schedule 1 to the Misuse of Drugs \n(Prescription and Control of Supply of cannabis for Medical Use) Regulations \n2019 (S.I. No. 262 of 2019)) and permitted for supply pursuant to those \nRegulations \n\nCannabis resin \n\nCathinone \n\n2-(4-Chloro-2,5-dimethoxyphenyl)-N-[(2methoxyphenyl)methyl]ethanamine (otherwise known as 25C-NBOMe) \n\n1-(4-Cyanobutyl)-N-(1-methyl-1-phenylethyl)-1H-indazole-3-carboxamide \n(otherwise known as CUMYL-4CN-BINACA) \n\n1-Cyclohexyl-4-(1,2-diphenylethyl)piperazine (otherwise known as MT45) \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\f4 [121] \n\nCoca leaf \n\nConcentrate of poppy straw \n\n3,4-Dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide \n(otherwise known as AH-7921) \n\n3,4-Dichloro-N-(2-dimethylamino-cyclohexyl)-N-methyl-benzamide \n(otherwise known as U-47700) \n\n[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4benzoxazin-6-yl]-1-naphthalenylmethanone \n\nN,N-Diethyltryptamine \n\n2,5-Dimethoxy-α,4-dimethylphenethylamine \n\nN,N-Dimethyltryptamine \n\n3-Dimethylheptyl-11-hydroxyhexahydrocannabinol \n\nEthyl phenyl(piperidin-2-yl)acetate (otherwise known as Ethylphenidate) \n\nEticyclidine \n\nEtryptamine \n\n[1-(5-Fluoropentyl)-1H-indol-3-yl](2,2,3,3tetramethylcyclopropyl)methanone (otherwise known as XLR-11) \n\n1-(2-Fluorophenyl)-2-methylaminopropan-1-one \n\n1-(3-Fluorophenyl)-2-methylaminopropan-1-one \n\n1-(4-Fluorophenyl)-2-methylaminopropan-1-one \n\n9-(Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10atetrahydrobenzo[c]chromen-1-ol \n\n[9-Hydroxy-6-methyl-3-[5-phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10aoctahydrophenanthridin-1-yl]acetate \n\nN-Hydroxy-tenamphetamine \n\n2-(4-Iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine \n(otherwise known as 25I-NBOMe) \n\nKhat (being the leaves of Catha edulis (Celastraceae)) \n\nLysergamide \n\nLysergide and other N-alkyl derivatives of lysergamide \n\nMescaline \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\f[121] 5 \n\nMethcathinone \n\n2-(3-Methoxyphenyl)-2-(ethylamino)cyclohexanone (otherwise known as \nmethoxetamine) \n\n1-(4-Methoxyphenyl)-2-(methylamino)propan-1-one \n\nMethyl (2S,4aR,6aR,7R,10aS,10bR)-9-acetyloxy-2-(furan-3-yl)6a,10b-dimethyl-4,10-dioxo-2,4a,5,6,7,8,9,10a-octahydro-1Hbenzo[f]isochromene-7-carboxylate (otherwise known as Salvinorin \nA) and any product, whether natural or otherwise, including any plant \nor plant material of any kind or description, which contains any \nproportion of the said substance \n\n2-Methylamino-1-(3,4-methylenedioxyphenyl)butan-1-one \n\n2-Methylamino-1-(3,4-methylenedioxyphenyl)propan-1-one \n\n4-Methyl-aminorex \n\nMethyl 2-[[1-(cyclohexylmethyl)indole-3-carbonyl]amino]-3,3dimethylbutanoate (otherwise known as MDMB CHMICA) \n\nMethyl (E)-2-[(2S,3S,7aS,12bS)-3-ethyl-7a-hydroxy-8-methoxy2,3,4,6,7,12b-hexahydro-1H-indolo[2,3a]quinolizin-2-yl]-3-methoxyprop-2enoate (otherwise known as 7-Hydroxymitragynine) and any product, \nwhether natural or otherwise, including any plant or plant material of any \nkind or description, which contains any proportion of the said substance \n\nMethyl (E)-2-[(2S,3S,12bS)-3-ethyl-8-methoxy-1,2,3,4,6,7,12,12boctahydroindolo[2,3a]quinolizin-2-yl]-3-methoxyprop-2-enoate (otherwise \nknown as Mitragynine) and any product, whether natural or otherwise, \nincluding any plant or plant material of any kind or description, which \ncontains any proportion of the said substance \n\nMethyl (2S)-2-{[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino}-3,3dimethylbutanoate (otherwise known as 5F-MDMB-PINACA) \n\nMethyl (2S)-2[[1-[(4-fluorophenyl)methyl]indazole-3-carbonyl]amino]-3methylbutanoate (otherwise known as FUB-AMB) \n\n4-Methyl-5-(4-methylphenyl)-4,5-dihydro-1,3-oxazol-2-amine (otherwise \nknown as 4,4’-DMAR) \n\nα-Methyl-4-(methylthio)phenethylamine \n\n1-(4-Methylphenyl)-2-methylaminopropan-1-one \n\n(1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone \n(otherwise known as UR-144) \n\nN-Methyl-1-(thiophen-2-yl)propan-2-amine (otherwise known as \nMethiopropamine) \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\f6 [121] \n\nPsilocin \n\nQuinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (otherwise known \nas Clockwork Orange, PB22) \n\nRaw opium \n\nRolicyclidine \n\nTenocyclidine \n\nN-[1-(2-Thenyl)-4-piperidyl]propionanilide \n\n(b) Any substance (not being bupropion, diethylpropion or pyrovalerone) \n\nstructurally derived from 2-amino-1-phenyl-1-propanone by modification in any \nof the following ways: \n\n(i) \n\nby substitution in the phenyl ring to any extent with alkyl, alkenyl, alkynyl, \nalkoxy, alkylthio, alkylenedioxy, haloalkyl or halo substituents, whether or \nnot further substituted in the phenyl ring by one or more other univalent \nsubstituents; \n\n(ii) \n\nby substitution at the 2- or 3-position of the propanone side-chain with an \nalkyl substituent; \n\n(iii) by substitution at the nitrogen atom with one or more alkyl or dialkyl \n\ngroups, or by inclusion of the nitrogen atom in a cyclic structure. \n\n(c) Any substance structurally derived from 2-amino-1-propanone by substitution at \nthe 1-position with any monocyclic, or fused-polycyclic ring system (not being a \nphenyl ring or alkylenedioxyphenyl ring system), whether or not the substance is \nfurther modified in any of the following ways: \n\n(i) \n\nby substitution in the ring system to any extent with alkyl, alkenyl, alkynyl, \nalkoxy, alkylthio, haloalkyl or halo substituents, whether or not further \nsubstituted in the ring system by one or more other univalent substituents; \n\n(ii) \n\nby substitution at the 3-position with an alkyl substituent; \n\n(iii) by substitution at the 2-amino nitrogen atom with one or more alkyl or \ndialkyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic \nstructure. \n\n(d) Any substance structurally derived from 3-(1-benzoyl)indole or 3-(1naphthoyl)indole by modification in any of the following ways: \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\f[121] 7 \n\n(i) \n\nby substitution at the nitrogen atom of the indole ring by alkyl, alkenyl, \ncycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl; \n\n(ii) \n\nby replacement of one or more hydrogen atoms of any of the substituents \nreferred to in clause (i), with a halo substituent; \n\nwhether or not further substituted in the indole ring to any extent and whether or not \nsubstituted in the phenyl or naphthyl ring to any extent. \n\n(e) \n\n1-Benzylpiperazine or any substance (not being a substance specified in Schedule \n3 of the Misuse of Drugs Regulations 2017) structurally derived from 1benzylpiperazine or 1-phenylpiperazine by modification in any of the following \nways: \n\n(i) \n\nby substitution at the second nitrogen atom of the piperazine ring with \nalkyl, benzyl, haloalkyl or phenyl groups; \n\n(ii) \n\nby substitution in the aromatic ring to any extent with alkyl, alkoxy, \nalkylenedioxy, halo or haloalkyl groups. \n\n(f) Any substance (not being a substance specified in Schedule 2 of the Misuse of \nDrugs Regulations 2017) structurally derived from fentanyl by modification in \none or more of the following ways, that is to say: \n\n(i) \n\nby replacement of the phenyl portion of the phenethyl group by any \nheteromonocycle whether or not further substituted in the heterocycle; \n\n(ii) \n\nby substitution in the phenethyl group with alkyl, alkenyl, alkoxy, \nhydroxy, halo, haloalkyl, amino or nitro groups; \n\n(iii) by substitution in the piperidine ring with alkyl or alkenyl groups; \n\n(iv) by substitution in the aniline ring with alkyl, alkoxy, alkylenedioxy, halo \n\nor haloalkyl groups; \n\n(v) \n\nby substitution at the 4-position of the piperidine ring with any \nalkoxycarbonyl or alkoxyalkyl or acyloxy group; \n\n(vi) by replacement of the N-propionyl group by another acyl group. \n\n(g) Any substance structurally derived from 2-(3-hydroxycyclohexyl)phenol by \n\nsubstitution at the 5-position of the phenolic ring by alkyl, alkenyl, \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\f8 [121] \n\ncycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not \nfurther substituted in the cyclohexyl ring to any extent. \n\n(h) Any substance structurally derived from 3-(1-naphthoyl)indole or 1H-indol-3yl-(1-naphthyl)methane by substitution at the nitrogen atom of the indole ring \nby alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, \nwhether or not further substituted in the indole ring to any extent and whether or \nnot substituted in the naphthyl ring to any extent. \n\n(i) Any substance structurally derived from 3-(1-naphthoyl)pyrrole by substitution \nat the nitrogen atom of the pyrrole ring by alkyl, alkenyl, cycloalkylmethyl, \ncycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in \nthe pyrrole ring to any extent and whether or not substituted in the naphthyl ring \nto any extent. \n\n(j) Any substance structurally derived from 1-(1-naphthylmethyl)indene by \nsubstitution at the 3-position of the indene ring by alkyl, alkenyl, \ncycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not \nfurther substituted in the indene ring to any extent and whether or not \nsubstituted in the naphthyl ring to any extent. \n\n(k) Any substance (not being a substance specified in Schedule 2 of the Misuse of \nDrugs Regulations 2017) structurally derived from pethidine by modification in \none or more of the following ways, that is to say: \n\n(i) \n\nby replacement of the 1-methyl group by an acyl, alkyl (whether or not \nunsaturated), benzyl or phenethyl group, whether or not further substituted; \n\n(ii) \n\nby substitution in the piperidine ring with alkyl or alkenyl groups or with \na propano bridge, whether or not further substituted; \n\n(iii) by substitution in the 4-phenyl ring with alkyl, alkoxy, aryloxy, halo or \n\nhaloalkyl groups; \n\n(iv) by replacement of the 4-ethoxycarbonyl by any other alkoxycarbonyl or \n\nany alkoxyalkyl or acyloxy group; \n\n(v) \n\nby formation of an N-oxide or of a quaternary base. \n\n(l) Any substance (not being methoxyphenamine) structurally derived from \nphenethylamine, an N-alkyl-phenethylamine, α-methylphenethylamine, an Nalkyl- α-methylphenethylamine, α-ethylphenethylamine, or an N-alkyl- α- \nethylphenethylamine by substitution in the ring to any extent with alkyl, alkoxy, \nalkylenedioxy or halo substituents, whether or not further substituted in the ring \nby one or more other univalent substituents. \n\n \n \n \n \n \n \n \n \n \n \n \n\f[121] 9 \n\n(m) Any substance structurally derived from 3-phenylacetylindole by substitution at \nthe nitrogen atom of the indole ring with alkyl, alkenyl, cycloalkylmethyl, \ncycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in \nthe indole ring to any extent and whether or not substituted in the phenyl ring to \nany extent. \n\n(n) Any fungus containing any proportion of Psilocin or of an ester of Psilocin. \n\n(o) \n\n1,2,3,4-Tetrahydronaphthalen-2-amine, 1,2-dihydronaphthalen-2-amine or 2,3dihydro-1H-inden-2-amine or any substance structurally derived from 1,2,3,4tetrahydronaphthalen-2-amine, 1,2-dihydronaphthalen-2-amine or 2,3-dihydro1H-inden-2-amine by modification in any of the following ways: \n\n(i) \n\nby substitution in the phenyl ring to any extent with alkyl, alkoxy, alkenyl, \nalkynyl, alkylthio, alkylenedioxy, haloalkyl, hydroxy or halo substituents, \nwhether or not further substituted by one or more other univalent \nsubstituents; \n\n(ii) \n\nby mono- or di-substitution at the nitrogen atom with alkyl, alkenyl, \nalkynyl or haloalkyl groups or by inclusion of the nitrogen atom in a cyclic \nstructure. \n\n(p) Any substance structurally derived from tryptamine or from a ring-hydroxy \ntryptamine by substitution at the nitrogen atom of the side-chain with one or more \nalkyl substituents but no other substituent”.", "text_norm": "1 following substance product namely- (a) n-(adamantan-1-yl)-1-(5-fluoropentyl)-1h-indazole-3-carboxamide (otherwise known clockwork orange 5f akb48) n- (2s)-1-amino-3 3-dimethyl-1-oxobutan-2yl -1-(cyclohexylmethyl)-1hindazole-3-carboxamide (otherwise known adb-chminaca) n-(1-amino-3 3-dimethyl-1-oxobutan-2yl)-1-(4-fluorobenzyl)-1h-indazole3-carboxamide (otherwise known adb-fubinaca) n- (2s)-1-amino-3-methyl-1-oxobutan-2-yl -1-(cyclohexylmethyl)-1hindazole-3-carboxamide (otherwise known ab-chminaca) n- (2s)-1-amino-3-methyl-1-oxobutan-2yl -1-pentyl-1h-indazole-3carboxamide (otherwise known ab-pinaca) 5-(2-aminopropyl)indole (otherwise known 5-it) 1-(1 3-benzodioxol-5-yl)-2-(1-pyrrolidinyl)-1-pentanone n-(1-benzyl-4-piperidyl)propionanilide 2-(4-bromo-2 5-dimethoxyphenyl)-n- (2methoxyphenyl)methyl ethanamine (otherwise known 25b-nbome) 1-(4-bromofuro 2 3-f 1 benzofuran-8-yl)propan-2-amine (otherwise known bromodragonfly) bufotenine cannabinol except contained cannabis cannabis resin cannabinol derivative dronabinol stereoisomers cannabis (not preparation specified paragraph 5 part 1 schedule 4 misuse drug regulation 2017 (s.i no 173 2017) preparation product specified schedule 1 misuse drug (prescription control supply cannabis medical use) regulation 2019 (s.i no 262 2019)) permitted supply pursuant regulation cannabis resin cathinone 2-(4-chloro-2 5-dimethoxyphenyl)-n- (2methoxyphenyl)methyl ethanamine (otherwise known 25c-nbome) 1-(4-cyanobutyl)-n-(1-methyl-1-phenylethyl)-1h-indazole-3-carboxamide (otherwise known cumyl-4cn-binaca) 1-cyclohexyl-4-(1 2-diphenylethyl)piperazine (otherwise known mt45) 4 121 coca leaf concentrate poppy straw 3 4-dichloro-n- 1-(dimethylamino)cyclohexyl methyl benzamide (otherwise known ah-7921) 3 4-dichloro-n-(2-dimethylamino-cyclohexyl)-n-methyl-benzamide (otherwise known u-47700) 2 3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo 1 2 3-de -1 4benzoxazin-6-yl -1-naphthalenylmethanone n n-diethyltryptamine 2 5-dimethoxy-a 4-dimethylphenethylamine n n-dimethyltryptamine 3-dimethylheptyl-11-hydroxyhexahydrocannabinol ethyl phenyl(piperidin-2-yl)acetate (otherwise known ethylphenidate) eticyclidine etryptamine 1-(5-fluoropentyl)-1h-indol-3-yl (2 2 3 3tetramethylcyclopropyl)methanone (otherwise known xlr-11) 1-(2-fluorophenyl)-2-methylaminopropan-1-one 1-(3-fluorophenyl)-2-methylaminopropan-1-one 1-(4-fluorophenyl)-2-methylaminopropan-1-one 9-(hydroxymethyl)-6 6-dimethyl-3-(2-methyloctan-2-yl)-6a 7 10 10atetrahydrobenzo c chromen-1-ol 9-hydroxy-6-methyl-3- 5-phenylpentan-2-yl oxy-5 6 6a 7 8 9 10 10aoctahydrophenanthridin-1-yl acetate n-hydroxy-tenamphetamine 2-(4-iodo-2 5-dimethoxyphenyl)-n- (2-methoxyphenyl)methyl ethanamine (otherwise known 25i-nbome) khat (being leaf catha edulis (celastraceae)) lysergamide lysergide n-alkyl derivative lysergamide mescaline 121 5 methcathinone 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone (otherwise known methoxetamine) 1-(4-methoxyphenyl)-2-(methylamino)propan-1-one methyl (2s 4ar 6ar 7r 10as 10br)-9-acetyloxy-2-(furan-3-yl)6a 10b-dimethyl-4 10-dioxo-2 4a 5 6 7 8 9 10a-octahydro-1hbenzo f isochromene-7-carboxylate (otherwise known salvinorin a) product whether natural otherwise including plant plant material kind description contains proportion said substance 2-methylamino-1-(3 4-methylenedioxyphenyl)butan-1-one 2-methylamino-1-(3 4-methylenedioxyphenyl)propan-1-one 4-methyl-aminorex methyl 2- 1-(cyclohexylmethyl)indole-3-carbonyl amino -3 3dimethylbutanoate (otherwise known mdmb chmica) methyl (e)-2- (2s 3 7as 12bs)-3-ethyl-7a-hydroxy-8-methoxy2 3 4 6 7 12b-hexahydro-1h-indolo 2 3a quinolizin-2-yl -3-methoxyprop-2enoate (otherwise known 7-hydroxymitragynine) product whether natural otherwise including plant plant material kind description contains proportion said substance methyl (e)-2- (2s 3 12bs)-3-ethyl-8-methoxy-1 2 3 4 6 7 12 12boctahydroindolo 2 3a quinolizin-2-yl -3-methoxyprop-2-enoate (otherwise known mitragynine) product whether natural otherwise including plant plant material kind description contains proportion said substance methyl (2s)-2- 1-(5-fluoropentyl)-1h-indazole-3-carbonyl amino -3 3dimethylbutanoate (otherwise known 5f-mdmb-pinaca) methyl (2s)-2 1- (4-fluorophenyl)methyl indazole-3-carbonyl amino -3methylbutanoate (otherwise known fub-amb) 4-methyl-5-(4-methylphenyl)-4 5-dihydro-1 3-oxazol-2-amine (otherwise known 4 4 -dmar) a-methyl-4-(methylthio)phenethylamine 1-(4-methylphenyl)-2-methylaminopropan-1-one (1-pentyl-1h-indol-3-yl)(2 2 3 3-tetramethylcyclopropyl)methanone (otherwise known ur-144) n-methyl-1-(thiophen-2-yl)propan-2-amine (otherwise known methiopropamine) 6 121 psilocin quinolin-8-yl 1-(5-fluoropentyl)-1h-indole-3-carboxylate (otherwise known clockwork orange pb22) raw opium rolicyclidine tenocyclidine n- 1-(2-thenyl)-4-piperidyl propionanilide (b) substance (not bupropion diethylpropion pyrovalerone) structurally derived 2-amino-1-phenyl-1-propanone modification following way (i) substitution phenyl ring extent alkyl alkenyl alkynyl alkoxy alkylthio alkylenedioxy haloalkyl halo substituents whether substituted phenyl ring one univalent substituents (ii) substitution 2- 3-position propanone side-chain alkyl substituent (iii) substitution nitrogen atom one alkyl dialkyl group inclusion nitrogen atom cyclic structure (c) substance structurally derived 2-amino-1-propanone substitution 1-position monocyclic fused-polycyclic ring system (not phenyl ring alkylenedioxyphenyl ring system) whether substance modified following way (i) substitution ring system extent alkyl alkenyl alkynyl alkoxy alkylthio haloalkyl halo substituents whether substituted ring system one univalent substituents (ii) substitution 3-position alkyl substituent (iii) substitution 2-amino nitrogen atom one alkyl dialkyl group inclusion 2-amino nitrogen atom cyclic structure (d) substance structurally derived 3-(1-benzoyl)indole 3-(1naphthoyl)indole modification following way 121 7 (i) substitution nitrogen atom indole ring alkyl alkenyl cycloalkylmethyl cycloalkylethyl 2-(4-morpholinyl)ethyl (ii) replacement one hydrogen atom substituents referred clause (i) halo substituent whether substituted indole ring extent whether substituted phenyl naphthyl ring extent (e) 1-benzylpiperazine substance (not substance specified schedule 3 misuse drug regulation 2017) structurally derived 1benzylpiperazine 1-phenylpiperazine modification following way (i) substitution second nitrogen atom piperazine ring alkyl benzyl haloalkyl phenyl group (ii) substitution aromatic ring extent alkyl alkoxy alkylenedioxy halo haloalkyl group (f) substance (not substance specified schedule 2 misuse drug regulation 2017) structurally derived fentanyl modification one following way say (i) replacement phenyl portion phenethyl group heteromonocycle whether substituted heterocycle (ii) substitution phenethyl group alkyl alkenyl alkoxy hydroxy halo haloalkyl amino nitro group (iii) substitution piperidine ring alkyl alkenyl group (iv) substitution aniline ring alkyl alkoxy alkylenedioxy halo haloalkyl group (v) substitution 4-position piperidine ring alkoxycarbonyl alkoxyalkyl acyloxy group (vi) replacement n-propionyl group another acyl group (g) substance structurally derived 2-(3-hydroxycyclohexyl)phenol substitution 5-position phenolic ring alkyl alkenyl 8 121 cycloalkylmethyl cycloalkylethyl 2-(4-morpholinyl)ethyl whether substituted cyclohexyl ring extent (h) substance structurally derived 3-(1-naphthoyl)indole 1h-indol-3yl-(1-naphthyl)methane substitution nitrogen atom indole ring alkyl alkenyl cycloalkylmethyl cycloalkylethyl 2-(4-morpholinyl)ethyl whether substituted indole ring extent whether substituted naphthyl ring extent (i) substance structurally derived 3-(1-naphthoyl)pyrrole substitution nitrogen atom pyrrole ring alkyl alkenyl cycloalkylmethyl cycloalkylethyl 2-(4-morpholinyl)ethyl whether substituted pyrrole ring extent whether substituted naphthyl ring extent (j) substance structurally derived 1-(1-naphthylmethyl)indene substitution 3-position indene ring alkyl alkenyl cycloalkylmethyl cycloalkylethyl 2-(4-morpholinyl)ethyl whether substituted indene ring extent whether substituted naphthyl ring extent (k) substance (not substance specified schedule 2 misuse drug regulation 2017) structurally derived pethidine modification one following way say (i) replacement 1-methyl group acyl alkyl (whether unsaturated) benzyl phenethyl group whether substituted (ii) substitution piperidine ring alkyl alkenyl group propano bridge whether substituted (iii) substitution 4-phenyl ring alkyl alkoxy aryloxy halo haloalkyl group (iv) replacement 4-ethoxycarbonyl alkoxycarbonyl alkoxyalkyl acyloxy group (v) formation n-oxide quaternary base (l) substance (not methoxyphenamine) structurally derived phenethylamine n-alkyl-phenethylamine a-methylphenethylamine nalkyl- a-methylphenethylamine a-ethylphenethylamine n-alkyl- a- ethylphenethylamine substitution ring extent alkyl alkoxy alkylenedioxy halo substituents whether substituted ring one univalent substituents 121 9 (m) substance structurally derived 3-phenylacetylindole substitution nitrogen atom indole ring alkyl alkenyl cycloalkylmethyl cycloalkylethyl 2-(4-morpholinyl)ethyl whether substituted indole ring extent whether substituted phenyl ring extent (n) fungus containing proportion psilocin ester psilocin (o) 1 2 3 4-tetrahydronaphthalen-2-amine 1 2-dihydronaphthalen-2-amine 2 3dihydro-1h-inden-2-amine substance structurally derived 1 2 3 4tetrahydronaphthalen-2-amine 1 2-dihydronaphthalen-2-amine 2 3-dihydro1h-inden-2-amine modification following way (i) substitution phenyl ring extent alkyl alkoxy alkenyl alkynyl alkylthio alkylenedioxy haloalkyl hydroxy halo substituents whether substituted one univalent substituents (ii) mono- di-substitution nitrogen atom alkyl alkenyl alkynyl haloalkyl group inclusion nitrogen atom cyclic structure (p) substance structurally derived tryptamine ring-hydroxy tryptamine substitution nitrogen atom side-chain one alkyl substituents substituent", "start_char": 971, "end_char": 13924, "source_path": "downloads\\2021\\2021_0121.pdf", "extraction_method": "pdfminer", "checksum": "sha256:ecdc49e5b74d5c6708ad4abbd34865aa1da0e76781d29133906ffbccd93668e5", "cross_refs": []}
{"doc_id": "si-2021-0121-reg-2", "parent_doc_id": "si-2021-0121", "section_id": "reg-2", "section_label": "Regulation 2.", "si_number": "S.I. No. 121 of 2021", "title": "(Amendment) Act 2016 (No. 9 of 2016)), 18 and 38 of the Misuse of Drugs Act", "year": 2021, "heading": "2. Any stereoisomeric form of a substance specified in paragraph 1.", "text_raw": "2. Any stereoisomeric form of a substance specified in paragraph 1.", "text_norm": "2 stereoisomeric form substance specified paragraph 1", "start_char": 13924, "end_char": 13994, "source_path": "downloads\\2021\\2021_0121.pdf", "extraction_method": "pdfminer", "checksum": "sha256:ecdc49e5b74d5c6708ad4abbd34865aa1da0e76781d29133906ffbccd93668e5", "cross_refs": []}
{"doc_id": "si-2021-0121-reg-3", "parent_doc_id": "si-2021-0121", "section_id": "reg-3", "section_label": "Regulation 3.", "si_number": "S.I. No. 121 of 2021", "title": "(Amendment) Act 2016 (No. 9 of 2016)), 18 and 38 of the Misuse of Drugs Act", "year": 2021, "heading": "3. Any ester or ether of a substance specified in paragraph 1 or 2.", "text_raw": "3. Any ester or ether of a substance specified in paragraph 1 or 2.", "text_norm": "3 ester ether substance specified paragraph 1 2", "start_char": 13994, "end_char": 14064, "source_path": "downloads\\2021\\2021_0121.pdf", "extraction_method": "pdfminer", "checksum": "sha256:ecdc49e5b74d5c6708ad4abbd34865aa1da0e76781d29133906ffbccd93668e5", "cross_refs": []}
{"doc_id": "si-2021-0121-reg-4", "parent_doc_id": "si-2021-0121", "section_id": "reg-4", "section_label": "Regulation 4.", "si_number": "S.I. No. 121 of 2021", "title": "(Amendment) Act 2016 (No. 9 of 2016)), 18 and 38 of the Misuse of Drugs Act", "year": 2021, "heading": "4. Any salt of a substance specified in any of paragraphs 1, 2 or 3.", "text_raw": "4. Any salt of a substance specified in any of paragraphs 1, 2 or 3.", "text_norm": "4 salt substance specified paragraph 1 2 3", "start_char": 14064, "end_char": 14135, "source_path": "downloads\\2021\\2021_0121.pdf", "extraction_method": "pdfminer", "checksum": "sha256:ecdc49e5b74d5c6708ad4abbd34865aa1da0e76781d29133906ffbccd93668e5", "cross_refs": []}
{"doc_id": "si-2021-0121-reg-5", "parent_doc_id": "si-2021-0121", "section_id": "reg-5", "section_label": "Regulation 5.", "si_number": "S.I. No. 121 of 2021", "title": "(Amendment) Act 2016 (No. 9 of 2016)), 18 and 38 of the Misuse of Drugs Act", "year": 2021, "heading": "5. Any preparation or other product containing any proportion of a", "text_raw": "5. Any preparation or other product containing any proportion of a \n\nsubstance or product specified in any of paragraphs 1, 2, 3 or 4, not being \na preparation specified in Schedule 5 of the Misuse of Drugs Regulations", "text_norm": "5 preparation product containing proportion substance product specified paragraph 1 2 3 4 preparation specified schedule 5 misuse drug regulation", "start_char": 14135, "end_char": 14355, "source_path": "downloads\\2021\\2021_0121.pdf", "extraction_method": "pdfminer", "checksum": "sha256:ecdc49e5b74d5c6708ad4abbd34865aa1da0e76781d29133906ffbccd93668e5", "cross_refs": []}
{"doc_id": "si-2021-0121-reg-2017", "parent_doc_id": "si-2021-0121", "section_id": "reg-2017", "section_label": "Regulation 2017.", "si_number": "S.I. No. 121 of 2021", "title": "(Amendment) Act 2016 (No. 9 of 2016)), 18 and 38 of the Misuse of Drugs Act", "year": 2021, "heading": "10 [121]", "text_raw": "2017. \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\f10 [121] \n\nGIVEN under my Official Seal, \n\n18 March, 2021. \n\nSTEPHEN DONNELLY, \nMinister for Health. \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n\f[121] 11", "text_norm": "2017 10 121 given official seal 18 march 2021 stephen donnelly minister health 121 11", "start_char": 14355, "end_char": 14545, "source_path": "downloads\\2021\\2021_0121.pdf", "extraction_method": "pdfminer", "checksum": "sha256:ecdc49e5b74d5c6708ad4abbd34865aa1da0e76781d29133906ffbccd93668e5", "cross_refs": []}
{"doc_id": "si-2021-0121-explanatory-note", "parent_doc_id": "si-2021-0121", "section_id": "explanatory-note", "section_label": "EXPLANATORY NOTE", "si_number": "S.I. No. 121 of 2021", "title": "(Amendment) Act 2016 (No. 9 of 2016)), 18 and 38 of the Misuse of Drugs Act", "year": 2021, "heading": "(This note is not part of the Instrument and does not purport to be a legal", "text_raw": "EXPLANATORY NOTE \n\n(This note is not part of the Instrument and does not purport to be a legal \ninterpretation.) \n\nThe purpose of these Regulations is to amend the Misuse of Drugs Regulations \n2017 by adding certain additional substances to schedule 1 of the Regulations. \n\nThese Regulations may be cited as the Misuse of Drugs (Amendment) \nRegulations 2021. \n\n \n \n \n \n \n \n \n\f12 [121] \n\nBAILE ÁTHA CLIATH \nARNA FHOILSIÚ AG OIFIG AN tSOLÁTHAIR \nLe ceannach díreach ó \nFOILSEACHÁIN RIALTAIS, \n52 FAICHE STIABHNA, BAILE ÁTHA CLIATH 2, \nD02 DR67. \n\nTeil: 076 110 6834 \nr-post: publications@opw.ie \n—————— \n\nDUBLIN \nPUBLISHED BY THE STATIONERY OFFICE \nTo be purchased from \nGOVERNMENT PUBLICATIONS, \n52 ST. STEPHEN'S GREEN, DUBLIN 2, \nD02 DR67. \n\nTel: 076 110 6834 \nE-mail: publications@opw.ie \n—————— \n\n€ 3.50 \n\n(DH-196) 75. 3/21. Propylon.", "text_norm": "explanatory note (this note part instrument purport legal interpretation.) purpose regulation amend misuse drug regulation 2017 adding certain additional substance schedule 1 regulation regulation may cited misuse drug (amendment) regulation 2021 12 121 baile atha cliath arna fhoilsiu ag oifig tsolathair le ceannach direach foilseachain rialtais 52 faiche stiabhna baile atha cliath 2 d02 dr67 teil 076 110 6834 r-post publication opw.ie ------------ dublin published stationery office purchased government publication 52 st stephen green dublin 2 d02 dr67 tel 076 110 6834 e-mail publication opw.ie ------------ eur 3.50 (dh-196) 75 3 21 propylon", "start_char": 14545, "end_char": 15381, "source_path": "downloads\\2021\\2021_0121.pdf", "extraction_method": "pdfminer", "checksum": "sha256:ecdc49e5b74d5c6708ad4abbd34865aa1da0e76781d29133906ffbccd93668e5", "cross_refs": []}
